ClinicalTrials.gov record
A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
ClinicalTrials.gov ID: NCT04365387
Public ClinicalTrials.gov record NCT04365387. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Subjects With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
Study identification
- NCT ID
- NCT04365387
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 242 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 54 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 5, 2020 (Actual)
- Primary completion
- Jul 7, 2023 (Actual)
- Completion
- Jul 7, 2023 (Actual)
- Last update posted
- Jun 1, 2026
2020 – 2023
United States locations
- U.S. sites
- 64
- U.S. states
- 23
- U.S. cities
- 56
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Galderma Investigational Site (Site#9922) | Phoenix | Arizona | 85018 | — |
| Galderma Investigational Site (Site#8873) | Scottsdale | Arizona | 85260 | — |
| Galderma Investigational Site (Site#8447) | Fort Smith | Arkansas | 72916 | — |
| Galderma Investigational Site (Site#8831) | Anaheim | California | 92801 | — |
| Galderma Investigational Site (Site#8854) | Canoga Park | California | 91303 | — |
| Galderma Investigational Site (Site#8578) | Cerritos | California | 90703 | — |
| Galderma Investigational Site (Site#8791) | Fresno | California | 93720 | — |
| Galderma Investigational Site (Site#8845) | Huntington Beach | California | 92647 | — |
| Galderma Investigational Site (Site#8833) | Inglewood | California | 90301 | — |
| Galderma Investigational Site 2 (Site#8833) | Inglewood | California | 90301 | — |
| Galderma Investigational Site (Site#8858) | Long Beach | California | 90806 | — |
| Galderma Investigational Site (Site#8130) | Los Angeles | California | 90045 | — |
| Galderma Investigational Site (Site#8813) | Los Angeles | California | 90057 | — |
| Galderma Investigational Site (Site#8837) | Pomona | California | 91767 | — |
| Galderma Investigational Site (SIte#8870) | Boca Raton | Florida | 33433 | — |
| Galderma Investigational Site (Site#8786) | Clearwater | Florida | 33765 | — |
| Galderma Investigational Site (Site#8792) | Doral | Florida | 33122 | — |
| Galderma Investigational Site (Site#8391) | Hialeah | Florida | 33013 | — |
| Galderma Investigational Site (Site#8836) | Jacksonville | Florida | 32256 | — |
| Galderma Investigational Site (Site#8850) | Margate | Florida | 33063 | — |
| Galderma Investigational Site (Site#8851) | Miami | Florida | 33135 | — |
| Galderma Investigational Site (Site#9921) | Miami Lakes | Florida | 33014 | — |
| Galderma Investigational Site (Site#8840) | Ocoee | Florida | 34761 | — |
| Galderma Investigational Site (Site#8788) | Orlando | Florida | 32801 | — |
| Galderma Investigational Site (Site#8213) | Ormond Beach | Florida | 32174 | — |
| Galderma Investigational Site (Site#8856) | Ormond Beach | Florida | 32174 | — |
| Galderma Investigational Site (Site#8856) | Ormond Beach | Florida | 33174 | — |
| Galderma Investigational Site (Site#8843) | Sweetwater | Florida | 33172 | — |
| Galderma Investigational Site (Site#8764) | Tampa | Florida | 33613 | — |
| Galderma Investigational Site 2 (Site#8816) | Tampa | Florida | 33613 | — |
| Galderma Investigational Site (Site#8839) | Tampa | Florida | 33615 | — |
| Galderma Investigational Site (Site#8739) | Normal | Illinois | 61761 | — |
| Galderma Investigational Site (Site#8142) | Indianapolis | Indiana | 46250 | — |
| Galderma Investigational Site (Site#8532) | Overland Park | Kansas | 66215 | — |
| Galderma Investigational Site (Site#8812) | Metairie | Louisiana | 70005 | — |
| Galderma Investigational Site (Site#8793) | Towson | Maryland | 21204 | — |
| Galderma Investigational Site (Site#8033) | Clinton Township | Michigan | 48038-1137 | — |
| Galderma Investigational Site (Site#8129) | Fort Gratiot | Michigan | 48059 | — |
| Galderma Investigational Site (Site#8849) | Troy | Michigan | 48084 | — |
| Galderma Investigational Site (Site#8876) | Bridgeton | Missouri | 63044 | — |
| Galderma Investigational Site (Site#8847) | Las Vegas | Nevada | 89118 | — |
| Galderma Investigational Site (Site#8848) | Las Vegas | Nevada | 89144 | — |
| Galderma Investigational Site 2 (Site#8864) | Las Vegas | Nevada | 89144 | — |
| Galderma Investigational Site (Site#8420) | Portsmouth | New Hampshire | 03801 | — |
| Galderma Investigational Site (Site#9924) | Raritan | New Jersey | 08869 | — |
| Galderma Investigational Site (Site#8828) | Kew Gardens | New York | 11415 | — |
| Galderma Investigational Site (Site#9919) | Raleigh | North Carolina | 27617 | — |
| Galderma Investigational Site (Site#8795) | Shelby | North Carolina | 28150 | — |
| Galderma Investigational Site (Site#8857) | Oklahoma City | Oklahoma | 73118 | — |
| Galderma Investigational Site (Site#8841) | Medford | Oregon | 97504 | — |
| Galderma Investigational Site (Site#8428) | Philadelphia | Pennsylvania | 19104 | — |
| Galderma Investigational Site (Site#8353) | Yardley | Pennsylvania | 19067 | — |
| Galderma Investigational Site (Site#8777) | Charleston | South Carolina | 29407 | — |
| Galderma Investigational Site (Site#8200) | Goodlettsville | Tennessee | 37072 | — |
| Galderma Investigational Site (Site#8846) | Austin | Texas | 78742 | — |
| Galderma Investigational Site (Site#8855) | Beaumont | Texas | 77702 | — |
| Galderma Investigational Site (Site#8245) | Dallas | Texas | 75231 | — |
| Galderma Investigational Site (Site#8868) | Houston | Texas | 77004 | — |
| Galderma Investigational Site (Site#8817) | Katy | Texas | 77494 | — |
| Galderma Investigational Site (Site#8787) | Plano | Texas | 75093 | — |
| Galderma Investigational Site (Site#8329) | San Antonio | Texas | 78229-3409 | — |
| Galderma Investigational Site (Site#8003) | Webster | Texas | 77598 | — |
| Galderma Investigational Site (Site#8844) | Orem | Utah | 84058 | — |
| Galderma Investigational Site (Site#9935) | Springville | Utah | 84663 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04365387, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 1, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04365387 live on ClinicalTrials.gov.